The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.

[1]  S. Cinieri,et al.  The molecular tumor board: a tool for the governance of precision oncology in the real world , 2021, Tumori.

[2]  I. Chirivella,et al.  Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study , 2021, British Journal of Cancer.

[3]  S. McCall,et al.  Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience , 2021, JCO precision oncology.

[4]  G. Fontanini,et al.  The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies. , 2021, Critical reviews in oncology/hematology.

[5]  M. Fassan,et al.  The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies☆ , 2021, ESMO open.

[6]  J. Sicklick,et al.  Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy , 2020, Nature Communications.

[7]  A. Kent,et al.  Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology , 2020, Biomedicine Hub.

[8]  A. Kent,et al.  Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine , 2020, Cancers.

[9]  Mark Robson,et al.  Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Claudio Luchini,et al.  Molecular Tumor Boards in Clinical Practice. , 2020, Trends in cancer.

[11]  T. Mok,et al.  Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). , 2020, Critical reviews in oncology/hematology.

[12]  Subha Madhavan,et al.  A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients , 2019, JAMIA open.

[13]  G. Scagliotti,et al.  International Association for the Study of Lung Cancer (IASLC) , 2019, Annals of Oncology.

[14]  Renato Martins,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  P. V. van Dam,et al.  Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer , 2018, ESMO Open.

[16]  Dae-Ho Lee.  Practical issues of biomarker-assisted targeted therapy in precision medicine and immuno-oncology era , 2018, ESMO Open.

[17]  Robyn L. Temple-Smolkin,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. , 2018, The Journal of molecular diagnostics : JMD.

[18]  M. Fassan.  Molecular Diagnostics in Pathology: Time for a Next-Generation Pathologist? , 2018, Archives of pathology & laboratory medicine.

[19]  S. Sleijfer,et al.  Molecular Tumor Boards: current practice and future needs , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  C. Rolfo,et al.  Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer , 2017, Expert review of molecular diagnostics.

[21]  Howard L. McLeod,et al.  Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. , 2017, The oncologist.

[22]  G. Troncone,et al.  Challenges and opportunities of next‐generation sequencing: a cytopathologist's perspective , 2015, Cytopathology : official journal of the British Society for Clinical Cytology.

[23]  J. Erdmann.  All aboard: Will molecular tumor boards help cancer patients? , 2015, Nature Medicine.

[24]  N. Petersen,et al.  Implementation of a regional virtual tumor board: a prospective study evaluating feasibility and provider acceptance. , 2014, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[25]  Etienne Rouleau,et al.  Guidance for laboratories performing molecular pathology for cancer patients , 2014, Journal of Clinical Pathology.

[26]  Dario de Biase,et al.  Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy) , 2013, PloS one.

[27]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[29]  R. Klitzman.  Consenting for molecular diagnostics. , 2015, Clinical chemistry.